I8H-MC-BDCP - ClinicalTrials.gov - NCT04450407
I8H-MC-BDCP - ClinicalTrials.gov - NCT04450407
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have a diagnosis of type 1 diabetes mellitus for at least 1 year
Participants must have been using multiple daily injections without interruption for at least 3 months
Participants must have HbA1c values of 5.6% to 9.5%, inclusive
Participants must have a body mass index (BMI) of ≤35 kilograms per meter squared (kg/m²)
Participants must NOT
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months prior to study screening
Participants must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
Participants must not have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)
Participants must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease
Participants must not have estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²
Participants must not have active or untreated cancer
Participants must not be on chronic (>14 days) systemic glucocorticoid therapy
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY3209590
Could I receive a Placebo?
no
Enrollment Goal
357
Trial Dates
July 2020 - September 2021
Trial Phase
2
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have a diagnosis of type 1 diabetes mellitus for at least 1 year
Participants must have been using multiple daily injections without interruption for at least 3 months
Participants must have HbA1c values of 5.6% to 9.5%, inclusive
Participants must have a body mass index (BMI) of ≤35 kilograms per meter squared (kg/m²)
Participants must NOT
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months prior to study screening
Participants must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
Participants must not have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)
Participants must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease
Participants must not have estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²
Participants must not have active or untreated cancer
Participants must not be on chronic (>14 days) systemic glucocorticoid therapy
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY3209590
Could I receive a Placebo?
no
Enrollment Goal
357
Trial Dates
July 2020 - September 2021
Trial Phase
2
Trial Locations
Hide locations not currently recruiting